Genelux Corp. (GNLX)

Genelux announced a public offering in January 2026, expecting to support operations into Q1 2027. Jason Litten was appointed as Chief Medical Officer in January 2026. The company participated in investor and healthcare conferences. Fourth quarter and full-year 2025 financial results were reported on March 19, 2026, with updates on the Phase 3 OnPrime/GOG-3076 trial and lung cancer data. GNLX's share price has been volatile, decreasing by 13.20% between March 27, 2025, and March 26, 2026.

Traditional product demand seasonality is not applicable to Genelux as its therapies are in clinical trials. However, September has historically shown the highest probability of positive returns for GNLX stock, while March has a lower probability.

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive solid tumors. Their lead product candidate, Olvi-Vec, is being developed for various cancers, utilizing the CHOICE™ platform. They also have early-stage therapies like V2ACT Immunotherapy and V-VET1. As of 2025, all revenue was from licensing agreements due to ongoing clinical trials.

Genelux Corp. is headquartered in Westlake Village, California, with R&D and manufacturing in San Diego. They have an exclusive licensing agreement with Newsoara BioPharma Co. Ltd. for Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau.

As of March 4, 2026, Genelux has an ESG risk rating of 40.3, categorized as "Severe Risk," indicating high exposure to material ESG issues. No specific events explicitly affecting Genelux Corp.'s brand reputation in the past year were found in the provided search results.

Institutional shareholders hold 20.34% of Genelux stock, with major holders including Woodward Diversified Capital LLC and Vanguard Group Inc. Insiders own 6.30%, with Thomas Zindrick being the largest individual shareholder. Retail investors hold a 73.36% stake.